← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Aminosalicylic acid and derivatives
sodium aminosalicylate
J04AA02
Forms & Strengths
- Oral powder packets: 4.19 g
- Delayed-release granules: 4 g per packet
Adult Dosing
- Tuberculosis: 4 g to 4.5 g orally three to four times daily (Total daily dose: 12 g to 16 g)
- Administer with meals to reduce gastrointestinal side effects
Pediatric Dosing
- Tuberculosis: 150 mg/kg to 300 mg/kg orally daily divided into 2 to 4 doses (Max: 12 g/day)
Indications
- Treatment of drug-resistant tuberculosis (MDR-TB) in conjunction with other tuberculostatic agents
Mechanism of Action
- Bacteriostatic agent specific for Mycobacterium tuberculosis
- Inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA)
Contraindications
- Hypersensitivity to aminosalicylic acid or its salts
- Severe renal impairment
- Patients with phenylketonuria (some formulations contain aspartame)
Adverse Reactions
- Gastrointestinal distress (nausea, vomiting, diarrhea, abdominal pain)
- Hypersensitivity reactions (fever, skin rash, hepatitis)
- Goiter with or without myxedema
- Blood dyscrasias (leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia)
- Malabsorption syndrome (steatorrhea, folate and vitamin B12 malabsorption)
Drug Interactions
- Diphenhydramine: May decrease absorption of aminosalicylic acid
- Rifampin: Serum concentrations of rifampin may be decreased when co-administered
- Vitamin B12: Long-term use may impair absorption of vitamin B12
- Digoxin: Serum concentrations of digoxin may be decreased
Curated Content: Needs Vetting Before Put to Clinical Use